Antithrombotic management of patients with nonvalvular atrial fibrillation and ischemic stroke or transient ischemic attack

Executive summary of the korean clinical practice guidelines for stroke

Keun Hwa Jung, Kyung Ho Yu, Young Dae Kim, Jong Moo Park, Keun Sik Hong, Joung Ho Rha, Sun U. Kwon, Hee Joon Bae, Jihoe Heo, Byung Chul Lee, Byung Woo Yoon

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Cardioembolic stroke related to nonvalvular atrial fibrillation is associated with a high recurrence rate and high mortality and morbidity. In this population, therefore, optimal anticoagulant therapy is required to prevent the occurrence of second stroke. Oral anticoagulant, warfarin has been traditionally used, but it is greatly limited by its narrow efficacy window, complex pharmacokinetics, and multiple drug interactions, thus requiring frequent blood monitoring. Recently, oral anticoagulants targeted for a specific coagulation component have been newly developed and tested in large clinical trials. Dabigatran, direct thrombin inhibitor, and rivaroxaban, apixaban, and edoxaban, inhibitors of factor Xa harbor great merits of rapid action time, short half-life, stable plasma concentration, and little drug interaction. Recently, large randomized clinical trials and meta-analyses have been published to show the efficacy and safety of the new oral anticoagulants compared with warfarin. Based on the results from recent clinical trials, we revised recommendations to apply optimal anticoagulant therapy in patients with nonvalvular atrial fibrillation and ischemic stroke or transient ischemic attack.

Original languageEnglish
Pages (from-to)210-215
Number of pages6
JournalJournal of Stroke
Volume17
Issue number2
DOIs
Publication statusPublished - 2015 May 1

Fingerprint

Transient Ischemic Attack
Practice Guidelines
Anticoagulants
Atrial Fibrillation
Stroke
Warfarin
Drug Interactions
Clinical Trials
Factor Xa
Antithrombins
Half-Life
Meta-Analysis
Randomized Controlled Trials
Pharmacokinetics
Morbidity
Safety
Recurrence
Mortality
Therapeutics
Population

All Science Journal Classification (ASJC) codes

  • Clinical Neurology
  • Cardiology and Cardiovascular Medicine

Cite this

Jung, Keun Hwa ; Yu, Kyung Ho ; Kim, Young Dae ; Park, Jong Moo ; Hong, Keun Sik ; Rha, Joung Ho ; Kwon, Sun U. ; Bae, Hee Joon ; Heo, Jihoe ; Lee, Byung Chul ; Yoon, Byung Woo. / Antithrombotic management of patients with nonvalvular atrial fibrillation and ischemic stroke or transient ischemic attack : Executive summary of the korean clinical practice guidelines for stroke. In: Journal of Stroke. 2015 ; Vol. 17, No. 2. pp. 210-215.
@article{4a6a4ec92e6f447eb6ef49f6b266f577,
title = "Antithrombotic management of patients with nonvalvular atrial fibrillation and ischemic stroke or transient ischemic attack: Executive summary of the korean clinical practice guidelines for stroke",
abstract = "Cardioembolic stroke related to nonvalvular atrial fibrillation is associated with a high recurrence rate and high mortality and morbidity. In this population, therefore, optimal anticoagulant therapy is required to prevent the occurrence of second stroke. Oral anticoagulant, warfarin has been traditionally used, but it is greatly limited by its narrow efficacy window, complex pharmacokinetics, and multiple drug interactions, thus requiring frequent blood monitoring. Recently, oral anticoagulants targeted for a specific coagulation component have been newly developed and tested in large clinical trials. Dabigatran, direct thrombin inhibitor, and rivaroxaban, apixaban, and edoxaban, inhibitors of factor Xa harbor great merits of rapid action time, short half-life, stable plasma concentration, and little drug interaction. Recently, large randomized clinical trials and meta-analyses have been published to show the efficacy and safety of the new oral anticoagulants compared with warfarin. Based on the results from recent clinical trials, we revised recommendations to apply optimal anticoagulant therapy in patients with nonvalvular atrial fibrillation and ischemic stroke or transient ischemic attack.",
author = "Jung, {Keun Hwa} and Yu, {Kyung Ho} and Kim, {Young Dae} and Park, {Jong Moo} and Hong, {Keun Sik} and Rha, {Joung Ho} and Kwon, {Sun U.} and Bae, {Hee Joon} and Jihoe Heo and Lee, {Byung Chul} and Yoon, {Byung Woo}",
year = "2015",
month = "5",
day = "1",
doi = "10.5853/jos.2015.17.2.210",
language = "English",
volume = "17",
pages = "210--215",
journal = "Journal of Stroke",
issn = "2287-6391",
publisher = "Korean Stroke Society",
number = "2",

}

Antithrombotic management of patients with nonvalvular atrial fibrillation and ischemic stroke or transient ischemic attack : Executive summary of the korean clinical practice guidelines for stroke. / Jung, Keun Hwa; Yu, Kyung Ho; Kim, Young Dae; Park, Jong Moo; Hong, Keun Sik; Rha, Joung Ho; Kwon, Sun U.; Bae, Hee Joon; Heo, Jihoe; Lee, Byung Chul; Yoon, Byung Woo.

In: Journal of Stroke, Vol. 17, No. 2, 01.05.2015, p. 210-215.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Antithrombotic management of patients with nonvalvular atrial fibrillation and ischemic stroke or transient ischemic attack

T2 - Executive summary of the korean clinical practice guidelines for stroke

AU - Jung, Keun Hwa

AU - Yu, Kyung Ho

AU - Kim, Young Dae

AU - Park, Jong Moo

AU - Hong, Keun Sik

AU - Rha, Joung Ho

AU - Kwon, Sun U.

AU - Bae, Hee Joon

AU - Heo, Jihoe

AU - Lee, Byung Chul

AU - Yoon, Byung Woo

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Cardioembolic stroke related to nonvalvular atrial fibrillation is associated with a high recurrence rate and high mortality and morbidity. In this population, therefore, optimal anticoagulant therapy is required to prevent the occurrence of second stroke. Oral anticoagulant, warfarin has been traditionally used, but it is greatly limited by its narrow efficacy window, complex pharmacokinetics, and multiple drug interactions, thus requiring frequent blood monitoring. Recently, oral anticoagulants targeted for a specific coagulation component have been newly developed and tested in large clinical trials. Dabigatran, direct thrombin inhibitor, and rivaroxaban, apixaban, and edoxaban, inhibitors of factor Xa harbor great merits of rapid action time, short half-life, stable plasma concentration, and little drug interaction. Recently, large randomized clinical trials and meta-analyses have been published to show the efficacy and safety of the new oral anticoagulants compared with warfarin. Based on the results from recent clinical trials, we revised recommendations to apply optimal anticoagulant therapy in patients with nonvalvular atrial fibrillation and ischemic stroke or transient ischemic attack.

AB - Cardioembolic stroke related to nonvalvular atrial fibrillation is associated with a high recurrence rate and high mortality and morbidity. In this population, therefore, optimal anticoagulant therapy is required to prevent the occurrence of second stroke. Oral anticoagulant, warfarin has been traditionally used, but it is greatly limited by its narrow efficacy window, complex pharmacokinetics, and multiple drug interactions, thus requiring frequent blood monitoring. Recently, oral anticoagulants targeted for a specific coagulation component have been newly developed and tested in large clinical trials. Dabigatran, direct thrombin inhibitor, and rivaroxaban, apixaban, and edoxaban, inhibitors of factor Xa harbor great merits of rapid action time, short half-life, stable plasma concentration, and little drug interaction. Recently, large randomized clinical trials and meta-analyses have been published to show the efficacy and safety of the new oral anticoagulants compared with warfarin. Based on the results from recent clinical trials, we revised recommendations to apply optimal anticoagulant therapy in patients with nonvalvular atrial fibrillation and ischemic stroke or transient ischemic attack.

UR - http://www.scopus.com/inward/record.url?scp=84983147485&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84983147485&partnerID=8YFLogxK

U2 - 10.5853/jos.2015.17.2.210

DO - 10.5853/jos.2015.17.2.210

M3 - Article

VL - 17

SP - 210

EP - 215

JO - Journal of Stroke

JF - Journal of Stroke

SN - 2287-6391

IS - 2

ER -